{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Sacramento&page=56&state=California", "query": { "state": "California", "city": "Sacramento", "page": 56 }, "page_size": 10 }, "pagination": { "page": 56, "page_size": 10, "total_count": 5563, "total_pages": 557, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Sacramento&page=57&state=California&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Sacramento&page=55&state=California&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T10:56:17.390Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00862459", "title": "Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Diseases", "Spinal Cord Diseases" ], "interventions": [ { "name": "Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)", "type": "DRUG" }, { "name": "Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)", "type": "DRUG" }, { "name": "Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)", "type": "DRUG" }, { "name": "OptiMARK~0.1 mmol/kg BW", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 237, "start_date": "2005-08", "completion_date": "2007-03", "has_results": true, "last_update_posted_date": "2014-01-13", "last_synced_at": "2026-11-15T10:56:17.390Z", "location_count": 20, "location_summary": "Sacramento, California • San Diego, California • Jacksonville, Florida + 16 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00862459" }, { "nct_id": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Bladder Carcinoma", "Breast Carcinoma", "Cervical Carcinoma", "Colon Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma", "Esophageal Carcinoma", "Exocrine Pancreas Carcinoma", "Gastric Carcinoma", "Glioma", "Head and Neck Carcinoma", "Hematopoietic and Lymphoid Cell Neoplasm", "Kidney Carcinoma", "Liver Carcinoma", "Lung Carcinoma", "Lymphoma", "Malignant Uterine Corpus Neoplasm", "Malignant Uterine Neoplasm", "Melanoma", "Multiple Myeloma", "Ovarian Carcinoma", "Prostate Carcinoma", "Rectal Carcinoma", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Cervical Carcinoma", "Recurrent Colon Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Recurrent Glioma", "Recurrent Head and Neck Carcinoma", "Recurrent Liver Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Malignant Uterine Corpus Neoplasm", "Recurrent Melanoma", "Recurrent Multiple Myeloma", "Recurrent Ovarian Carcinoma", "Recurrent Pancreatic Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Rectal Carcinoma", "Recurrent Skin Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma", "Skin Carcinoma", "Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" }, { "name": "Afatinib", "type": "DRUG" }, { "name": "Afatinib Dimaleate", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Copanlisib", "type": "DRUG" }, { "name": "Copanlisib Hydrochloride", "type": "DRUG" }, { "name": "Crizotinib", "type": "DRUG" }, { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Dabrafenib Mesylate", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Defactinib", "type": "DRUG" }, { "name": "Defactinib Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Fexagratinib", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Larotrectinib", "type": "DRUG" }, { "name": "Larotrectinib Sulfate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "PI3K-beta Inhibitor GSK2636771", "type": "DRUG" }, { "name": "Radiologic Examination", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Relatlimab", "type": "BIOLOGICAL" }, { "name": "Sapanisertib", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" }, { "name": "Taselisib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" }, { "name": "Ulixertinib", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6452, "start_date": "2015-08-17", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-15T10:56:17.390Z", "location_count": 1405, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02465060" }, { "nct_id": "NCT00078988", "title": "High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Brain Tumor", "Central Nervous System Tumor" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "isotretinoin", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "20 Years", "sex": "ALL", "summary": "Up to 20 Years" }, "enrollment_count": 1, "start_date": "2004-10", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2015-05-07", "last_synced_at": "2026-11-15T10:56:17.390Z", "location_count": 52, "location_summary": "Little Rock, Arkansas • Oakland, California • Sacramento, California + 45 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Oakland", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00078988" }, { "nct_id": "NCT03981549", "title": "Treatment of Central Retinal Vein Occlusion Using Stem Cells Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Central Retinal Vein Occlusion" ], "interventions": [ { "name": "Autologous Bone Marrow CD34+ Stem Cells", "type": "BIOLOGICAL" }, { "name": "Sham Therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "The Emmes Company, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2019-10-22", "completion_date": "2023-11-09", "has_results": true, "last_update_posted_date": "2024-12-02", "last_synced_at": "2026-11-15T10:56:17.390Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03981549" }, { "nct_id": "NCT03386474", "title": "Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "Brolucizumab 6 mg", "type": "DRUG" }, { "name": "Aflibercept 2 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 151, "start_date": "2018-01-15", "completion_date": "2018-09-06", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-11-15T10:56:17.390Z", "location_count": 63, "location_summary": "Peoria, Arizona • Phoenix, Arizona • Arcadia, California + 56 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03386474" }, { "nct_id": "NCT07243652", "title": "I-DECIDE After Bronchiolitis Hospitalization", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Bronchiolitis Acute" ], "interventions": [ { "name": "Moderate-Resource Implementation Strategy", "type": "OTHER" }, { "name": "High-Resource Implementation Strategy", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Seattle Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Months", "maximum_age": "24 Months", "sex": "ALL", "summary": "0 Months to 24 Months" }, "enrollment_count": 2700, "start_date": "2025-11-01", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-11-15T10:56:17.390Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 53 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Lodi", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07243652" }, { "nct_id": "NCT05395858", "title": "A Study to Learn More About Treatment With Damoctocog Alfa Pegol, How it is Used in Every Day Practice (\"Real-World\"), and How Satisfied People Who Receive Damoctocog Alfa Pegol Are in United States (US) Hemophilia Treatment Centers", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hemophilia A" ], "interventions": [ { "name": "No intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 14, "start_date": "2023-01-17", "completion_date": "2023-11-06", "has_results": false, "last_update_posted_date": "2023-11-28", "last_synced_at": "2026-11-15T10:56:17.390Z", "location_count": 3, "location_summary": "Sacramento, California • New Orleans, Louisiana • Minneapolis, Minnesota", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05395858" }, { "nct_id": "NCT00963885", "title": "A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "RO5190591 (Danoprevir)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2009-08", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-11-15T10:56:17.390Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00963885" }, { "nct_id": "NCT04644315", "title": "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Colorectal Neoplasms", "Melanoma", "Pancreatic Neoplasms", "Sarcoma", "Ovarian Neoplasms", "Brain Neoplasms", "Thyroid Neoplasms", "Neuroendocrine Tumors", "Cholangiocarcinoma", "Salivary Gland Neoplasms", "Head and Neck Neoplasms", "Thyroid Cancer, Papillary", "Lymphoma, Large-Cell, Anaplastic", "Neoplasms by Site", "Respiratory Tract Neoplasms", "Thoracic Neoplasms", "Respiratory Tract Diseases", "Carcinoma, Bronchogenic", "Bronchial Neoplasms", "Intestinal Neoplasms", "Gastrointestinal Neoplasms", "Digestive System Neoplasms", "Digestive System Diseases", "Gastrointestinal Diseases", "Colonic Diseases", "Intestinal Diseases", "Central Nervous System" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-05-24", "completion_date": "2022-05-16", "has_results": true, "last_update_posted_date": "2023-08-07", "last_synced_at": "2026-11-15T10:56:17.390Z", "location_count": 29, "location_summary": "Culver City, California • Los Angeles, California • Sacramento, California + 21 more", "locations": [ { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04644315" }, { "nct_id": "NCT04020978", "title": "Parametric PET of Genitourinary Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Genitourinary Cancer" ], "interventions": [ { "name": "Parametric PET/CT", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "21 Years to 100 Years" }, "enrollment_count": 11, "start_date": "2019-07-16", "completion_date": "2023-12-15", "has_results": false, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-11-15T10:56:17.390Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04020978" } ] }